Under the IRA, small molecule drugs and biologics that otherwise qualify for selection first become eligible for price negotiation seven and eleven years, respectively, after U.S. FDA approval…While the impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
